Document is current
Any future updates will be listed below
-
Authors
Corbett, Anne
Sander-Long, Millie
Ashton, Nicholas J. https://orcid.org/0000-0002-3579-8804
Huber, Hanna
Vavra, Jakub
Braun-Wohlfahrt, Luisa Sophie https://orcid.org/0009-0007-7845-7851
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Montoliu-Gaya, Laia https://orcid.org/0000-0001-7684-6318
Cummings, Jeffrey https://orcid.org/0000-0001-8944-4158
Bateman, Freya https://orcid.org/0000-0002-4329-0912
Davis, Christine
Ballard, Clive https://orcid.org/0000-0003-0022-5632
-
Funding
Funding for this research was provided by:
NIHR Exeter Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 12 January 2026
Accepted: 23 March 2026
First Online: 6 May 2026
Competing interests
: Anne Corbett declares consultancy work for Novartis, Addex, Suven, Sunovion, Janssen, and Acadia pharmaceutical companies and grant funding from Novo Nordisk, ReMynd, Therini Bio pharmaceutical companies. Nicholas Ashton has received consultancy/speaker fees from Alamar Biosciences, Bioartic, Biogen, Eli-Lilly, Neurogen Biomarking, Roche, Spear Bio, Quanterix, and Vigil Neurosciences. Laia Montoliu-Gaya has received consultancy/speaker fees from Quanterix and Esteve. Clive Ballard has received consulting fees from Acadia Pharmaceutical Company, AARP, Addex Pharmaceutical Company, Eli Lily, Enterin Pharmaceutical Company, GWPharm, H. Lundbeck Pharmaceutical Company, Novartis Pharmaceutical Company, Janssen Pharmaceuticals, Johnson & Johnson Pharmaceutical, Novo Nordisk Pharmaceutical Company, Orion Corp Pharmaceutical Company, Otsuka America Pharm Inc, Sunovion Pharm. Inc, Suven Pharmaceutical Company, Roche Pharmaceutical Company, Biogen Pharmaceutical Company, Synexus Clinical Research Organization, and tauX Pharmaceutical Company, and research funding from Synexus Clinical Research Organization, Roche Pharmaceutical Company, Novo Nordisk Pharmaceutical Company, and Novartis Pharmaceutical Company. Jeffrey Cummings has provided consultation to Acadia, Acumen, ALZpath, AnnovisBio, Artery, Axsome, Biogen, Bristol-Myers Squibb, Eisai, Fosun, GAP Foundation, Hummingbird Diagnostics, IGC, Janssen, Julius Clinical, Kinoxis, Lilly, LSP/eqt, Merck, MoCA Cognition, Novo Nordisk, NSC Therapeutics, Otsuka, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, Sinaptica, and T-Neuro pharmaceutical, assessment, and investment companies. He is supported by NIGMS grant P20GM109025; NIA R35AG71476; NIA R25AG083721; NINDS RO1NS139383; Alzheimer’s Disease Drug Discovery Foundation (ADDF); Ted and Maria Quirk Endowment; Joy Chambers-Grundy Endowment. Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of CERimmune Therapeutics (outside submitted work). All other authors declare no competing interests.
